Advertise on podcast: The Critical Path Institute Podcast

Critical Path Institute’s (C-Path) newest podcast episode picks up on the 20th Anniversary commemoration and provides an insightful outlook to what’s coming next for C-Path as we mold the future of drug development. This engaging conversation between C-Path CEO Klaus Romero and President/COO Kristen Swingle highlights how C-Path's core competencies in regulatory science, biomarkers, data, clinical outcome assessment, and modeling and analytics accelerate therapeutic innovation. As the pharmaceutical industry transitions into a new century marked by personalized medicine and advanced therapeutic modalities, such as advanced therapeutic medical products (including, but not limited to gene editing and cell therapies), and C-Path’s role in advancing modern drug development paradigms. The speakers emphasize the necessity to adopt novel scientific frameworks that maintain rigorous evidence standards while embracing personalization and innovation. Key themes discussed include the rise of decentralized clinical trials supported by digital health technologies, the transformative potential of real-world evidence from real-world data, and the promising role of artificial intelligence (AI) in drug development — though caution is urged to ensure AI outputs are scientifically sound and ethically applied. The discussion stresses the crucial involvement of patients, advocating for patient-focused drug development to place the patient voice at the center of innovation. The episode also explores C-Path’s initiatives to bridge the “valley of death” in translational research in order to empower academicians to move discoveries from the lab to practical drug development with regulatory guidance and funding support.

This Critical Path Institute (C-Path) podcast episode celebrates C-Path's 20 years of impactful innovation in accelerating drug development by connecting scientific, clinical, regulatory, and data-driven disciplines. Founded in 2005 in response to the FDA’s 2004 Critical Path Initiative, C-Path was established as a neutral, nonprofit organization to facilitate public-private partnerships involving industry, academia, patient groups, and regulators. These partnerships aim to identify bottlenecks in drug development and create actionable scientific solutions that make the process more efficient for all stakeholders. Over the past two decades, C-Path has transformed challenging therapeutic areas—such as Alzheimer’s disease, rare diseases like Duchenne muscular dystrophy and Friedreich’s ataxia, tuberculosis, polycystic kidney disease, and type 1 diabetes prevention—from stagnant or neglected fields into thriving areas with new drug approvals and robust development pipelines. This success was largely driven by integrating diverse data sources (clinical trials, observational studies, patient registries, electronic health records) into comprehensive platforms, enabling the development and qualification of biomarkers, clinical outcome assessments, and quantitative modeling tools. Join C-Path CEO Klaus Romero and President/COO Kristen Swingle Part One of this podcast for a final celebration of our 20 years of impact, as well as a year in review of all of the accomplishments C-Path made through 2025 alone.

Critical Path Institute (C-Path CEO Klaus Romero is joined by International Neonatal Consortium Executive Director Kanwaljit Singh to discuss the unique challenges and innovations in neonatal drug development. Neonates, particularly premature babies, are not simply smaller versions of adults or older children; their rapidly evolving physiology and complex medical conditions require specialized approaches in drug development. Singh explains how the INC fosters collaboration across pharmaceutical companies, academic researchers, healthcare professionals, parents, and global regulatory agencies to accelerate neonatal drug development. A key achievement of the consortium has been the development of the Neonatal Adverse Event Severity Scale (NAESS), which standardizes the assessment of adverse events in neonates, a critical need since traditional adult or pediatric adverse event scales are inadequate for this population. The consortium is now working on NAESS 2.0, expanding the scale and creating a digital tool to facilitate its use in clinical trials. Another major focus is the integration of real-world data and clinical trial data, creating one of the world’s largest neonatal databases with over 380,000 patient records from hospitals across the U.S., Canada, UK, and Japan. This database supports the development of disease progression models, such as for bronchopulmonary dysplasia (BPD), a common and severe lung condition in premature neonates, and the establishment of standardized reference ranges for lab values in neonatal intensive care units (NICUs). INC is also initiating efforts around neonatal brain injury, collecting data to validate biomarkers as surrogate endpoints, which could accelerate clinical trials by providing earlier indicators of treatment efficacy.

In the latest episode of the Critical Path Institute (C-Path) Podcast, C-Path CEO and podcast moderator Klaus Romero sits down the Vice President of our Quantitative Medicine Program Vice President Dr. Shu Chin Ma. Shu Chin and Klaus discuss how C-Path integrates mathematics, statistics, artificial intelligence, and digital technologies to accelerate drug development. She clarifies how the QuantMed program uses mathematical models to understand how drugs move through the body and how the body reacts, enabling optimized clinical trial designs to increase success rates, reduce risks, and improve patient safety. By simulating various clinical trial scenarios, these models help tailor treatments to individual patient characteristics, addressing variability in responses and disease progression. Shu Chin also emphasizes that clinical trials are complex endeavors requiring detailed knowledge about patient populations, disease stages, and other treatments. Modeling helps differentiate natural disease progression from drug effects, which is crucial to accurately assessing a drug’s efficacy and safety. Even unsuccessful trials provide valuable data that can refine future trial designs. The approach also has significant economic benefits by reducing trial time and patient burden.

This newest podcast episode from Critical Path Institute’s® (C-Path) Electronic Clinical Outcome Assessment (eCOA) Consortium in the eCOA Conversations series focuses on the adoption of sensor-based digital health technologies (DHTs) in clinical research, with concentrations on the current landscape, challenges, and future opportunities. The expert panel of Dr. Elena Izmailova, Former Chief Scientific Officer at Koneksa Health, Dr. Christine Guo, Chief Scientific Officer at Ametris, and Managing Partner of Patient Cloud at Medidata, Mark Matson, join eCOA Executive Director, Scottie Kern, to share their diverse journeys in digital health and insights on how these technologies can transform clinical trials. The panelists agree that while sensor-based DHTs are gaining traction, the field is still in its early stages and not yet commoditized like biomarker assays. Key barriers include limited familiarity within biopharma sponsors, lack of technical expertise, the complexity of data collection and interpretation, and regulatory uncertainties. They underscore the critical need for education across clinical, regulatory, and operational teams, as well as the importance of multidisciplinary collaboration, including data scientists and biomedical engineers.

This newest Critical Path Institute (C-Path) podcast episode provides an in-depth exploration of one of C-Path's core competencies: the Data Collaboration Center (DCC). Led by Ramona Walsh, Director of the DCC, and Rick Liwski, Chief Technology Officer, Rick and Ramona join C-Path CEO Klaus Romero to discuss how data drives C-Path’s efforts to accelerate drug development. The podcast explains the types of data integrated by =DCC — including clinical trial data, electronic health records (EHR), imaging, digital device data, and preclinical findings—and how the team manages complex challenges of data acquisition, standardization, privacy, and accessibility. DCC emphasizes Findable, Accessible, Interoperable, and Reusable (FAIR) data principles and implements rigorous curation to ensure data quality and regulatory compliance. The episode highlights DCC’s pivotal role in assembling large, integrated datasets crucial for developing drug development tools, especially in challenging areas such as rare and orphan diseases where patient populations are limited. The conversation also outlines the distinctions and interplay between data management, data engineering, and data science within C-Path, as well as the evolution of the Data and Analytics Platform (DAP), which securely hosts and facilitates collaborative research on over 700,000 patient datasets spanning 450+ studies. Looking to the future, the leaders share a vision emphasizing federated data access across multiple platforms and the integration of artificial intelligence and machine learning to enhance data processing, curation, and analytical efficiencies. The episode wraps up by reinforcing the DCC’s critical mission to convert complex data into actionable insights that move drug development forward and facilitate regulatory review.

Welcome to the latest Critical Path Institute Podcast episode—the first in the Electronic Clinical Outcome Assessment (eCOA) Conversations series. This engaging panel features industry veterans reacting to the question, “What makes a good eCOA partner?” In addition to host Scottie Kern, Executive Director of C-Path's eCOA Consortium, the panel includes Dr. Florence Mowlem, Chief Science Officer at uMotif, YPrime's Vice President of eCOA and Patient Technologies, Dr. Karl McEvoy, and Brian Lillis, Director of Clinical Outcome Technologies at ICON. Highlights: Value of Partnerships: Successful ECOA implementation relies on strong partnerships between sponsors and vendors, enabling efficient communication and problem-solving outside trial pressures. Diverse Expertise: The panelists highlight the importance of diverse backgrounds among team members to navigate the complexities of ECOA effectively. Quality of Data: Emphasis is placed on the necessity of robust data collection mechanisms to accurately reflect the drug’s impact, particularly in therapeutic areas like neurology and dermatology. Early Engagement: Engaging with ECOA vendors early in the study design process can streamline implementation, reducing last-minute challenges and enhancing efficiency. Honest Communication: Transparency in discussing challenges, including acknowledging when things go wrong, fosters trust and strengthens partnerships. Operational Efficiency: The need to prevent delays in study timelines emphasizes the importance of an ECOA vendor’s operational capabilities in ensuring smooth study conduct. Shared Knowledge: Leveraging the collective expertise of both sponsors and ECOA vendors can address regulatory uncertainties and enhance trial efficacy.

In our latest episode of the C-Path podcast, “Connecting the Dots Between Type 1 Diabetes and Parkinson’s Disease,” we explore the surprising intersections between these two conditions in recognition of Parkinson’s Awareness Day. Join C-Path CEO Klaus Romero as he moderates a powerful conversation with Diane Stephenson, Vice President of Neurology and Executive Director of the Critical Path for Parkinson’s Consortium, and Joe Hedrick, Executive Director of the Type 1 Diabetes Consortium. Together, they share key insights from their collaborative work at C-Path, revealing how cross-disease learnings, patient perspectives, and data-driven strategies are helping to accelerate progress in drug development.

The inaugural episode of the Critical Path Institute (C-Path) podcast serves as a platform to discuss the intersection of drug development, clinical science, and public health. Hosted by CEO Klaus Romero and guest Cheryl Coon, the episode explores how clinical outcome assessments (COAs) are essential in measuring patient experiences and determining drug efficacy.